1. Home
  2. MDWD vs NNBR Comparison

MDWD vs NNBR Comparison

Compare MDWD & NNBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • NNBR
  • Stock Information
  • Founded
  • MDWD 2000
  • NNBR 1980
  • Country
  • MDWD Israel
  • NNBR United States
  • Employees
  • MDWD N/A
  • NNBR N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • NNBR Industrial Machinery/Components
  • Sector
  • MDWD Health Care
  • NNBR Industrials
  • Exchange
  • MDWD Nasdaq
  • NNBR Nasdaq
  • Market Cap
  • MDWD 184.8M
  • NNBR 197.7M
  • IPO Year
  • MDWD 2014
  • NNBR 1994
  • Fundamental
  • Price
  • MDWD $17.75
  • NNBR $3.18
  • Analyst Decision
  • MDWD Strong Buy
  • NNBR
  • Analyst Count
  • MDWD 1
  • NNBR 0
  • Target Price
  • MDWD $25.00
  • NNBR N/A
  • AVG Volume (30 Days)
  • MDWD 56.9K
  • NNBR 151.0K
  • Earning Date
  • MDWD 11-26-2024
  • NNBR 10-30-2024
  • Dividend Yield
  • MDWD N/A
  • NNBR N/A
  • EPS Growth
  • MDWD N/A
  • NNBR N/A
  • EPS
  • MDWD N/A
  • NNBR N/A
  • Revenue
  • MDWD $19,720,000.00
  • NNBR $470,310,000.00
  • Revenue This Year
  • MDWD $10.37
  • NNBR N/A
  • Revenue Next Year
  • MDWD $26.36
  • NNBR $0.71
  • P/E Ratio
  • MDWD N/A
  • NNBR N/A
  • Revenue Growth
  • MDWD N/A
  • NNBR N/A
  • 52 Week Low
  • MDWD $11.04
  • NNBR $2.84
  • 52 Week High
  • MDWD $24.00
  • NNBR $5.40
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 53.40
  • NNBR 32.41
  • Support Level
  • MDWD $17.33
  • NNBR $3.06
  • Resistance Level
  • MDWD $18.25
  • NNBR $3.50
  • Average True Range (ATR)
  • MDWD 0.75
  • NNBR 0.19
  • MACD
  • MDWD 0.05
  • NNBR -0.06
  • Stochastic Oscillator
  • MDWD 73.68
  • NNBR 12.77

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About NNBR NN Inc.

NN Inc is a diversified industrial company that combines engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision solutions and components. It operates in two business segments: mobile solutions and power solutions. The mobile solutions segment involves growth in the general industrial and automotive end markets. Its power solutions segment involves growth in the electrical and aerospace and defense end markets. It also operates in China, Mexico, Brazil, Germany, and other countries.

Share on Social Networks: